Signal transducers and activators of transcription (STATs) play a pleomorphic role in signal transduction, similarly to an oncogene. Suppressors of cytokine signaling (SOCS) inhibit STAT pathways. In breast cancer, little is known about the correlation among STATs, SOCS, and clinicopathological/biological features. Therefore, we investigated p-STAT3 (activated form of STAT3) and SOCS-1/3 expression, and clarified their correlation. Immunohistochemical staining for p-STAT3 antigen was performed in 74 surgically resected primary breast cancers. Real-time RT-PCR was used to measure mRNA expression of SOCS-1 and SOCS-3. There were no significant correlations between p-STAT3 expression and clinicopathological/biological features. SOCS-3 mRNA expression in the lymph nodepositive group was significantly lower than that in the negative group (p=0.013). Among three groups divided based on the number of involved lymph nodes (node-negative group, 1-3 involved nodes group, 4 or more involved nodes group), the group with 4 or more involved nodes had the lowest expression of SOCS-3 (p=0.043). Correlations were not seen between SOCS-1 and SOCS-3 expression and other clinicopathological/biological features, except for blood vessel invasion. There were no statistical correlations between either SOCS-1 or SOCS-3 mRNA expression and p-STAT3 expression. Reduced expression of SOCS-3 is closely related to lymph node metastasis. Therefore, SOCS-3 may be a good predictor for lymph node metastasis.
Abstract. Cancer cells induce proliferation and local accumulation of immunosuppressive cells, such as FOXP3-positive cells known as regulatory T cells (Tregs), leading to tumorinduced immune tolerance. Although cancer chemotherapy is usually considered immunosuppressive, some chemotherapeutic agents activate an anticancer immune response. Therefore, we postulated that the number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy (PSC) correlates with therapeutic outcomes in patients with breast cancer. Between September 2000 and January 2005, we examined 93 patients with breast cancer diagnosed by core-needle biopsy and treated with PSC. Core-needle biopsy (CNB) and surgical resected specimens were stained with a FOXP3 mouse monoclonal antibody to compare the numbers of FOXP3-positive cells in the tumors before and after PSC. A median cut-off value of >16.3/high power field (HPF) and >6.6/HPF defined high numbers of Tregs in CNB and in surgical specimens, respectively. We then assigned the patients into 4 groups (HH, high number of FOXP3-positive cells in both CNB and surgical specimen; LL, low number in both specimens; HL, high in CNB and low in the surgical specimen; LH, low in CNB and high in surgical specimen). Lymph vessel invasion-positive, clinically non-responder and ER-negative tumors contained significantly more FOXP3-positive cells after PSC (p=0.04, p=0.03 and p=0.04, respectively). Prognosis was better among patients with low numbers than high numbers of FOXP3-positive cells both in CNB and in surgically resected specimens. In multivariate analysis, LL group demonstrated significantly better recurrence-free survival with risk ratio of 5.81 (95%CI, 1.09-107.5; p=0.04) rather than that of non-LL group (LH, HL and HH). These findings suggest that the number of FOXP3-positive cells identified during PSC represents a promising predictive factor that might also be an important therapeutic target for breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.